Fluidigm Completes C1™ Single-Cell Auto Prep System Early Access Program

  Fluidigm Completes C1™ Single-Cell Auto Prep System Early Access Program

       Oversubscribed Program Includes World’s Leading Research Centers

Business Wire

SOUTH SAN FRANCISCO, Calif. -- January 2, 2013

Fluidigm Corporation (NASDAQ:FLDM) announced that its C[1]™ Single-Cell Auto
Prep system Early Access Program (EAP) has concluded. The EAP originally
targeted 25 customers that would gain early access to the new platform,
protocols and consumables. The program attracted significant interest, filling
up weeks before its expected end-of-2012 deadline. To accommodate interested
customers, the company allowed oversubscription of the program.

"We have been excited and humbled by the enthusiastic reception the C[1]
system has received. Our customers have demonstrated a high level of interest
in the C[1] Early Access Program and the number of them that have signed up to
participate is clearly a record for Fluidigm,” said Gajus Worthington,
Fluidigm President and Chief Executive Officer. “The C[1] system is the most
powerful device for single-cell genomics available today because it enables a
wide range of genomic applications for our customers to discover and validate
novel transcripts in heterogeneous cell populations. We are just at the
beginning stages of an important market that will fuel genomic discovery over
the next decade.”

The C[1] Single-Cell Auto Prep System enables researchers to study cell
differentiation, measure individual cell responses to specific stimuli, verify
critical disease biomarkers, validate RNAi knockdown, and conduct candidate
drug screens. “We are thrilled to be working with an elite set of customers in
our Early Access Program. They represent a global group of scientists from the
world’s leading genomics research institutions. They have a genuine enthusiasm
about the prospect of applying C[1] system capabilities to their research and
many have begun experimental design and initial work on the systems. We
believe they will generate some breakthrough biological discoveries,” added
Worthington.

"As one of the first academic users of the Fluidigm C[1] Single Cell Auto Prep
system, my research team at UC San Diego will benefit by the development of
this advanced, single-cell technology. The system will support our commitment
to engaging our expertise in RNA and genome-wide computational methods to
deciphering heterogeneity in RNA processing in single cells, especially in the
developing nervous system and in neurodegenerative diseases,” noted Gene Yeo,
PhD, MBA, Assistant Professor, Department of Cellular and Molecular Medicine,
UC San Diego.

“Single-cell analyses are critical for our cellular reprogramming research
because each cell undergoes a fate change in a unique way. Averaging the
changes over many cells masks important reprogramming events in individual
cells that dramatically alter their fate,” said Deepak Srivastava, Director of
Cardiovascular and Stem Cell Research, Gladstone Institutes. “We are thrilled
to be part of the Fluidigm C[1] Single-Cell Auto Prep System’s Early Access
Program and look forward to using this exciting new technology to accelerate
our single-cell research efforts.”

“We are delighted to be one of the first users of the Fluidigm C[1] system.
One of our first projects will involve the analysis of neurons directly
converted from skin fibroblasts. The C[1] system will allow us to look at
markers specific for subtypes of neurons at a single-cell resolution while
assessing the conversion rate collectively in the population of converted
neurons,” said Seth Crosby, Director, Partnerships and Alliances at Washington
University School of Medicine. “The Fluidigm C[1] Single-Cell Auto Prep System
will be available in our facility on a fee-for-service basis for both WashU
and non-WashU researchers,” Crosby added.

“The C[1] system allows us to capture up to 96 individual cells at one time
and prepare them for further analysis,” says Vivian Gersuk, PhD, manager of
the Genomics Core Laboratory of the Benaroya Research Institute. “We can study
hundreds to thousands of genes in each of these cells, allowing us to produce
huge amounts of data in a matter of hours.”

The C[1] Single-Cell Auto Prep System is the first commercially available
platform for automated isolation and preparation of individual cells for
genomic analysis. The C[1] system, based on Fluidigm’s innovative microfluidic
technology, enables a researcher to isolate, process and summarize the unique
gene expression profiles of individual cells rapidly and reliably. For the
first time, a researcher can easily isolate single cells, extract RNA, then
reverse transcribe and amplify mRNA transcripts to ultimately detect and
analyze cell activity — dramatically reducing the variability and technical
errors caused by multi-platform workflows that have been previously used. By
delivering an integrated workflow, Fluidigm is enabling researchers to
implement targeted gene expression, miRNA analysis and whole transcriptome
analysis in a more efficient and cost-effective manner.

Fluidigm’s Early Access Program for the C[1] system provided a select group of
customers with the preferred access of instruments equipped with a package of
startup consumables (integrated fluidic circuits (IFCs) and reagents), and
provides first access to new application protocols or analysis tools. The EAP
participants actively contribute information about their experiences with the
C[1] system to Fluidigm to accelerate the development of new platform
capabilities. The C[1] system is specifically designed to work seamlessly with
the Fluidigm BioMark™ HD System to enhance the workflow and reliability of
data for scientists studying single-cell genomics.

The C[1] Single-Cell Auto Prep System consists of:

  *C[1 ]Single-Cell Auto Prep instrument that provides breakthrough bench-top
    automation of isolation, lysis and amplification performed on single
    cells.
  *C[1] Single-Cell Auto Prep Array IFCs that facilitate capture and highly
    paralleled preparation of up to 96 individual cells.
  *C[1] Single-Cell Auto Prep Reagent Kit, a pre-formulated “ready to use”
    reagent kit that supports cell suspension, lysis and purification.

For more information about the C[1] Single Cell Auto Prep system, please visit
www.fluidigm.com/c1system.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to Fluidigm’s new C[1] system, Fluidigm’s expectations with respect
to the development of a market for single cell genomic analysis and discovery,
Fluidigm’s plans, objectives, expectations and strategies relating to the C[1]
system, and potential developments in the markets that the C[1] system is
anticipated to target. Forward-looking statements are subject to numerous
risks and uncertainties that could cause actual results to differ materially
from currently anticipated results, including challenges inherent in
developing, manufacturing, and launching new products and risks relating to
research and development activities and the growth of new and developing
markets. Information on these and additional risks affecting Fluidigm’s
business and operating results are contained in its filings with the
Securities and Exchange Commission, including its most recently filed
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. These
forward-looking statements speak only as of the date hereof and Fluidigm
disclaims any obligation to update these statements.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems
for growth markets in the life science and agricultural biotechnology, or
Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of
instruments and consumables, including integrated fluidic circuits (IFCs),
assays and other reagents. These systems are designed to significantly
simplify experimental workflow, increase throughput and reduce costs, while
providing the excellent data quality demanded by customers. Fluidigm actively
markets four microfluidic systems, including thirteen different IFCs, to
leading academic institutions, diagnostic laboratories, and pharmaceutical,
biotechnology and Ag-Bio companies. Fluidigm products are marketed for
research purposes only (not for diagnostic use).

For more information, please visit www.fluidigm.com.

Fluidigm, the Fluidigm logo, C[1] and BioMark, are trademarks or registered
trademarks of Fluidigm Corporation. All other trademarks are the property of
their respective owners.

Contact:

Fluidigm Corporation
Howard High – Press Relations, 650-266-6081 (Office) or 510-786-7378 (Mobile)
howard.high@fluidigm.com